Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
Immunology
Immunotherapy
Oesophageal Cancer
Oncology
Radiotherapy
Surgery
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Jun 2022
07 Jun 2022
Historique:
received:
03
12
2021
revised:
19
02
2022
accepted:
26
04
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
12
7
2022
Statut:
ppublish
Résumé
In the contemporary era of cancer immunotherapy, an abundance of clinical and translational studies have reported radiotherapy (RT) and immunotherapies as a viable option for immunomodulation of many cancer subtypes, with many related clinical trials ongoing. In locally advanced disease, chemotherapy or chemoradiotherapy followed by surgical excision of the tumour remain the principal treatment strategy in oesophageal adenocarcinoma (OAC), however, the use of the host immune system to improve anti-tumour immunity is rapidly garnering increased support in the curative setting. To immunophenotype OAC patients' immune checkpoint (IC) expression with and without radiation and evaluate the effects of checkpoint blockade on cell viability. In the contemporary era of cancer immunotherapy, an abundance of studies have demonstrated that combination RT and IC inhibitors (ICIs) are effective in the immunomodulation of many cancer subtypes, with many related clinical trials ongoing. Although surgical excision and elimination of tumour cells by chemotherapy or chemoradiotherapy remains the gold standard approach in OAC, the propagation of anti-tumour immune responses is rapidly garnering increased support in the curative setting. The aim of this body of work was to immunophenotype OAC patients' IC expression with and without radiation and to establish the impact of checkpoint blockade on cell viability. This study was a hybrid combination of We identified that conventional dosing and hypofractionated approaches resulted in increased IC expression (PD-1, PD-L1, TIM3, TIGIT) The findings of the current study demonstrate synergistic potential for the use of ICIs and ionising radiation to potentiate established anti-tumour responses in the neoadjuvant setting and is of particular interest in those with advanced disease, adverse features of tumour biology and poor treatment responses to conventional therapies.
Sections du résumé
BACKGROUND
BACKGROUND
In the contemporary era of cancer immunotherapy, an abundance of clinical and translational studies have reported radiotherapy (RT) and immunotherapies as a viable option for immunomodulation of many cancer subtypes, with many related clinical trials ongoing. In locally advanced disease, chemotherapy or chemoradiotherapy followed by surgical excision of the tumour remain the principal treatment strategy in oesophageal adenocarcinoma (OAC), however, the use of the host immune system to improve anti-tumour immunity is rapidly garnering increased support in the curative setting.
AIM
OBJECTIVE
To immunophenotype OAC patients' immune checkpoint (IC) expression with and without radiation and evaluate the effects of checkpoint blockade on cell viability.
METHODS
METHODS
In the contemporary era of cancer immunotherapy, an abundance of studies have demonstrated that combination RT and IC inhibitors (ICIs) are effective in the immunomodulation of many cancer subtypes, with many related clinical trials ongoing. Although surgical excision and elimination of tumour cells by chemotherapy or chemoradiotherapy remains the gold standard approach in OAC, the propagation of anti-tumour immune responses is rapidly garnering increased support in the curative setting. The aim of this body of work was to immunophenotype OAC patients' IC expression with and without radiation and to establish the impact of checkpoint blockade on cell viability. This study was a hybrid combination of
RESULTS
RESULTS
We identified that conventional dosing and hypofractionated approaches resulted in increased IC expression (PD-1, PD-L1, TIM3, TIGIT)
CONCLUSION
CONCLUSIONS
The findings of the current study demonstrate synergistic potential for the use of ICIs and ionising radiation to potentiate established anti-tumour responses in the neoadjuvant setting and is of particular interest in those with advanced disease, adverse features of tumour biology and poor treatment responses to conventional therapies.
Identifiants
pubmed: 35800186
doi: 10.3748/wjg.v28.i21.2302
pmc: PMC9185220
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Placenta Growth Factor
144589-93-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2302-2319Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: There are no conflicts of interest to report.
Références
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Esophagus. 2020 Apr;17(2):122-126
pubmed: 31912332
Radiat Oncol. 2020 Jan 17;15(1):17
pubmed: 31952507
Lancet Oncol. 2019 Nov;20(11):1506-1517
pubmed: 31582355
Oncoimmunology. 2018 Mar 15;7(7):e1440168
pubmed: 29900043
Mol Immunol. 2017 Mar;83:13-22
pubmed: 28092803
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8328-33
pubmed: 20404142
Oncotarget. 2015 Nov 10;6(35):37588-99
pubmed: 26439988
Nat Rev Cancer. 2020 Apr;20(4):203-217
pubmed: 32161398
Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1082-1089
pubmed: 33539968
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32843492
J Immunother Cancer. 2016 Aug 16;4:45
pubmed: 27532020
Lancet. 2017 Nov 25;390(10110):2383-2396
pubmed: 28648400
Cancer Lett. 2021 Apr 1;502:84-96
pubmed: 33450360
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Ther Adv Med Oncol. 2020 May 26;12:1758835920926822
pubmed: 32518598
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
J Biomed Sci. 2013 Jun 21;20:39
pubmed: 23799978
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
Sci Rep. 2016 Jun 08;6:27528
pubmed: 27273624
Nat Rev Dis Primers. 2017 Jul 27;3:17048
pubmed: 28748917
Ann Surg. 2013 Nov;258(5):784-92; discussion 792
pubmed: 24045450
Int J Cancer. 2019 Aug 15;145(4):1111-1124
pubmed: 30719701
Br J Surg. 2017 Dec;104(13):1816-1828
pubmed: 28944954
Oncoimmunology. 2014 Apr 25;3:e28518
pubmed: 25071979
JCI Insight. 2020 Apr 9;5(7):
pubmed: 32271164
Front Immunol. 2021 Sep 21;12:723609
pubmed: 34621270
Lancet Oncol. 2012 Jan;13(1):43-54
pubmed: 22169269
Oncol Lett. 2017 Aug;14(2):1561-1567
pubmed: 28789380
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Cancer Res Treat. 2021 Jan;53(1):172-183
pubmed: 32898941
Oncotarget. 2017 Mar 7;8(10):16430-16444
pubmed: 28147314
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Radiother Oncol. 2021 Apr;157:32-39
pubmed: 33453312
ESMO Open. 2020 Nov;5(6):e001107
pubmed: 33208490
Trends Immunol. 2016 Aug;37(8):557-568
pubmed: 27389961
Radiother Oncol. 2021 Jan;154:187-193
pubmed: 32916236
Mod Pathol. 2020 Sep;33(9):1753-1763
pubmed: 32350416
J Immunol. 2013 Sep 1;191(5):2829-36
pubmed: 23918985
Front Oncol. 2021 Mar 26;11:654684
pubmed: 33842369
Front Oncol. 2020 Feb 27;10:221
pubmed: 32175278
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7):
pubmed: 28716888
Front Oncol. 2018 Jul 06;8:264
pubmed: 30035102
Expert Opin Biol Ther. 2020 Jan;20(1):15-22
pubmed: 31608707
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
JCI Insight. 2020 Aug 20;5(16):
pubmed: 32814710
Crit Rev Immunol. 2009;29(3):187-201
pubmed: 19538134
J Exp Med. 2015 Aug 24;212(9):1433-48
pubmed: 26261265
Front Oncol. 2020 Aug 28;10:1540
pubmed: 32984011
Crit Rev Clin Lab Sci. 2011 Jul-Aug;48(4):155-70
pubmed: 22035340
Front Oncol. 2020 Jun 04;10:891
pubmed: 32582553
Immunity. 2018 Sep 18;49(3):490-503.e4
pubmed: 30170810
J Immunother Cancer. 2018 Jun 4;6(1):46
pubmed: 29866197
Oncol Rep. 2014 Nov;32(5):2086-92
pubmed: 25120098
Clin Oncol (R Coll Radiol). 2019 Jun;31(6):356-364
pubmed: 30737068
Radiat Res. 2010 Dec;174(6):703-11
pubmed: 21128793
Cancer Med. 2019 Jul;8(8):3710-3718
pubmed: 31119872
Ann Thorac Surg. 2020 May;109(5):1551-1557
pubmed: 31987829
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Front Med (Lausanne). 2019 Nov 07;6:244
pubmed: 31788476
Cancers (Basel). 2020 Aug 05;12(8):
pubmed: 32764371
J Clin Oncol. 2002 Mar 1;20(5):1167-74
pubmed: 11870157